Medifast (MED) Accounts Payables (2010 - 2026)

Medifast (MED) has 17 years of Accounts Payables data on file, last reported at $38.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 26.15% year-over-year to $38.3 million; the trailing twelve-month figure through Mar 2026 stood at $38.3 million (down 26.15% YoY), and the FY2025 full-year result was $38.4 million, down 32.1% from the prior year.
• Accounts Payables for Q1 2026 stood at $38.3 million, roughly flat from $38.4 million in the prior quarter.
• Across five years, Accounts Payables topped out at $174.4 million in Q1 2022 and bottomed at $38.3 million in Q1 2026.
• The 5-year median for Accounts Payables is $71.2 million (2024), against an average of $87.8 million.
• The widest annual swing landed in 2022, when Accounts Payables grew 23.45%; it then sank 41.78% in 2025.
• A 5-year view of Accounts Payables shows it stood at $134.7 million in 2022, then sank by 35.84% to $86.4 million in 2023, then plunged by 34.62% to $56.5 million in 2024, then slumped by 32.1% to $38.4 million in 2025, then retreated by 0.25% to $38.3 million in 2026.
• The last three Accounts Payables figures came in at $38.3 million (Q1 2026), $38.4 million (Q4 2025), and $41.2 million (Q3 2025), per Business Quant data.

Peer Comparison